Clinical Trial Update: Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240) [Phase 3]

View source ↗

Summary

Phase 3 trial of pembrolizumab vs best supportive care in previously treated advanced hepatocellular carcinoma completed; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatocellular Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2020-02-17